

Christophe Legendre

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3230168/publications.pdf>

Version: 2024-02-01

192
papers

10,818
citations

34105

52
h-index

36028

97
g-index

208
all docs

208
docs citations

208
times ranked

9113
citing authors

#	ARTICLE	IF	CITATIONS
1	Kidney transplantation from expanded criteria donors: an increased risk of urinary complications â€“ the UriNary Complications Of Renal Transplant (UNyCORT) study. <i>BJU International</i> , 2022, 129, 225-233.	2.5	5
2	Outcomes of kidneyâ€™transplanted patients with history of intestinal reconstruction of the urinary tract. <i>BJUI Compass</i> , 2022, 3, 75-85.	1.3	2
3	Long-term survival benefit from dual kidney transplantation using kidneys from donors with very extended criteriaâ€™a French cohort between 2002 and 2014. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 982-990.	0.7	1
4	Erythrocytosis associated with IgA nephropathy. <i>EBioMedicine</i> , 2022, 75, 103785.	6.1	2
5	The sexual dimorphism of kidney growth in mice and humans. <i>Kidney International</i> , 2022, 102, 78-95.	5.2	10
6	Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with Omicron infection. <i>Kidney International</i> , 2022, 101, 1290-1293.	5.2	25
7	MO1021: Long-Term Outcomes After Conversion to a Belatacept-Based Immunosuppression in Kidney Transplant: A Matched Cohort Study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
8	FC 105: Multidimensional Prognostication Tool for Kidney Transplant Patient Survival: The Mortality Mbox. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0
9	Management of post-transplant recurrent focal and segmental glomerulosclerosis. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1994-1996.	0.7	3
10	Trajectories of glomerular filtration rate and progression to end stage kidney disease afterâ€™kidney transplantation. <i>Kidney International</i> , 2021, 99, 186-197.	5.2	40
11	Poor kidney graft survival in anorexia nervosa patients. <i>Eating and Weight Disorders</i> , 2021, 26, 1447-1455.	2.5	1
12	COVID-19 severity in kidney transplant recipients is similar to nontransplant patients with similar comorbidities. <i>American Journal of Transplantation</i> , 2021, 21, 1285-1294.	4.7	69
13	Encrusted Urinary Tract Infections Due to Corynebacteria Species. <i>Kidney International Reports</i> , 2021, 6, 179-186.	0.8	7
14	Increased incidence and unusual presentations of CMV disease in kidney transplant recipients after conversion to belatacept. <i>American Journal of Transplantation</i> , 2021, 21, 2448-2458.	4.7	31
15	Assessment of the Utility of Kidney Histology as a Basis for Discarding Organs in the United States: A Comparison of International Transplant Practices and Outcomes. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 397-409.	6.1	40
16	HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients. <i>Kidney International</i> , 2021, 99, 671-685.	5.2	24
17	Time-dependent lymphocyte count after transplantation is associated with higher risk of graft failure and death. <i>Kidney International</i> , 2021, 99, 1189-1201.	5.2	8
18	Temporal trends in living kidney donation in France between 2007 and 2017. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 730-738.	0.7	11

#	ARTICLE	IF	CITATIONS
19	Dissociation of humoral and cellular immune responses in kidney transplant recipients with EBV mucocutaneous ulcer. <i>Transplant Infectious Disease</i> , 2021, 23, e13552.	1.7	5
20	Rituximab for recurrence of primary focal segmental glomerulosclerosis after kidney transplantation: Results of a nationwide study. <i>American Journal of Transplantation</i> , 2021, 21, 3021-3033.	4.7	8
21	Decline and loss of anti-SARS-CoV-2 antibodies in kidney transplant recipients in the 6 months following SARS-CoV-2 infection. <i>Kidney International</i> , 2021, 99, 486-488.	5.2	30
22	The spectrum of kidney biopsies in hospitalized patients with COVID-19, acute kidney injury and/or proteinuria. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1253-1262.	0.7	54
23	Ig-responsive relapsing inflammatory syndrome following COVID-19 in a kidney transplant recipient. <i>Kidney International</i> , 2021, 99, 767-768.	5.2	3
24	Renal transplantation outcomes in obese patients: a French cohort-based study. <i>BMC Nephrology</i> , 2021, 22, 79.	1.8	12
25	Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated With Belatacept. <i>Transplantation</i> , 2021, 105, e94-e95.	1.0	105
26	FC 05 PERCENTILES OF NORMAL MEASURED GLOMERULAR FILTRATION RATE BASED ON DATA FROM LIVING KIDNEY DONORS. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.7	0
27	Living kidney donor evaluation for all candidates with normal estimated GFR for age. <i>Transplant International</i> , 2021, 34, 1123-1133.	1.6	3
28	Ravulizumab for the Treatment of aHUS in Adults: Improving Quality of Life. <i>Kidney International Reports</i> , 2021, 6, 1489-1491.	0.8	5
29	A kidney discard decision strategy based on zero-time histology analysis could lead to an unjustified increase in the organ turnaround rate among ECD. <i>Transplant International</i> , 2021, 34, 1506-1516.	1.6	1
30	The Case Membranous nephropathy after alemtuzumab treatment. <i>Kidney International</i> , 2021, 100, 249-250.	5.2	1
31	Cohort study: Outcomes of kidney transplantation in patients with prosthetic heart valves. <i>Transplant International</i> , 2021, 34, 2297-2304.	1.6	1
32	The Case Cardiac tamponade in a kidney transplant recipient with chronic inflammation. <i>Kidney International</i> , 2021, 100, 487-488.	5.2	0
33	Weak antibody response to three doses of mRNA vaccine in kidney transplant recipients treated with belatacept. <i>American Journal of Transplantation</i> , 2021, 21, 4043-4051.	4.7	84
34	Outcome of pretransplant melanoma after solid organ transplantation: an observational study. <i>Transplant International</i> , 2021, 34, 2154-2165.	1.6	0
35	Solid Organ Transplantation in the Era of COVID-19: Lessons from France. <i>Transplantation</i> , 2021, 105, 61-66.	1.0	26
36	COVID-19: A One-center Experience in Paris. <i>Transplantation Direct</i> , 2021, 7, e647.	1.6	1

#	ARTICLE	IF	CITATIONS
37	Application of the iBox prognostication system as a surrogate endpoint in the TRANSFORM randomised controlled trial: proof-of-concept study. <i>BMJ Open</i> , 2021, 11, e052138.	1.9	24
38	Timing of Kidney Clamping and Deceased Donor Kidney Transplant Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1704-1714.	4.5	4
39	Dynamic prediction of renal survival among deeply phenotyped kidney transplant recipients using artificial intelligence: an observational, international, multicohort study. <i>The Lancet Digital Health</i> , 2021, 3, e795-e805.	12.3	25
40	CRISPR/Cas9-Engineered HLA-Deleted Glomerular Endothelial Cells as a Tool to Predict Pathogenic Non-HLA Antibodies in Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 3231-3251.	6.1	8
41	Central nervous system complications in adult cystinosis patients. <i>Journal of Inherited Metabolic Disease</i> , 2020, 43, 348-356.	3.6	14
42	Association of blood bicarbonate and pH with mineral metabolism disturbance and outcome after kidney transplantation. <i>American Journal of Transplantation</i> , 2020, 20, 1063-1075.	4.7	11
43	Long-term outcome of methylmalonic aciduria after kidney, liver, or combined liver-kidney transplantation: The French experience. <i>Journal of Inherited Metabolic Disease</i> , 2020, 43, 234-243.	3.6	20
44	Reassessment of the clinical impact of preformed donor-specific anti-HLA-Cw antibodies in kidney transplantation. <i>American Journal of Transplantation</i> , 2020, 20, 1365-1374.	4.7	20
45	COVID-19 in Patients on Maintenance Dialysis in the Paris Region. <i>Kidney International Reports</i> , 2020, 5, 1535-1544.	0.8	49
46	Efficacy and Safety of Direct Oral Anticoagulants in Kidney Transplantation: A Single-center Pilot Experience. <i>Transplantation</i> , 2020, 104, 2625-2631.	1.0	15
47	Deciphering the Prognostic and Predictive Value of Urinary CXCL10 in Kidney Recipients With BK Virus Reactivation. <i>Frontiers in Immunology</i> , 2020, 11, 604353.	4.8	9
48	Conversion From Belatacept to Another Immunosuppressive Regimen in Maintenance Kidney-Transplantation Patients. <i>Kidney International Reports</i> , 2020, 5, 2195-2201.	0.8	4
49	The weekend effect in kidney transplantation outcomes: a French cohort-based study. <i>Transplant International</i> , 2020, 33, 1030-1039.	1.6	4
50	Should kidney allografts from old donors be allocated only to old recipients?. <i>Transplant International</i> , 2020, 33, 849-857.	1.6	12
51	Comparison of machine perfusion versus cold storage in kidney transplant recipients from expanded criteria donors: a cohort-based study. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1051-1059.	0.7	8
52	Predictive value of mixed antigen screen beads in pre-transplant assessment of HLA immunization in solid organ transplant recipients. <i>Clinical Transplantation</i> , 2020, 34, e14002.	1.6	3
53	Development and validation of an optimized integrative model using urinary chemokines for noninvasive diagnosis of acute allograft rejection. <i>American Journal of Transplantation</i> , 2020, 20, 3462-3476.	4.7	38
54	Induction therapy in kidney transplant recipients: Description of the practices according to the calendar period from the French multicentric DIVAT cohort. <i>PLoS ONE</i> , 2020, 15, e0240929.	2.5	8

#	ARTICLE	IF	CITATIONS
55	Editorial: Transplantation of Marginal Organs—Immunological Aspects and Therapeutic Perspectives. <i>Frontiers in Immunology</i> , 2020, 11, 612576.	4.8	2
56	Comparison of graft and patient survival according to the transplantation centre policy for 1-year screening biopsy among stable kidney recipients: a propensity score-based study. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 703-711.	0.7	9
57	Lifetime ESKD risk stratification for living kidney donor studies. <i>American Journal of Transplantation</i> , 2019, 19, 2658-2659.	4.7	3
58	Evidence-based practice: Guidance for using everolimus in combination with low-exposure calcineurin inhibitors as initial immunosuppression in kidney transplant patients. <i>Transplantation Reviews</i> , 2019, 33, 191-199.	2.9	12
59	Disparities in Acceptance of Deceased Donor Kidneys Between the United States and France and Estimated Effects of Increased US Acceptance. <i>JAMA Internal Medicine</i> , 2019, 179, 1365.	5.1	125
60	Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. <i>BMJ: British Medical Journal</i> , 2019, 366, l4923.	2.3	191
61	Osmoregulation Performance and Kidney Transplant Outcome. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 1282-1293.	6.1	6
62	Management of Kaposi sarcoma after solid organ transplantation: A European retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 448-455.	1.2	31
63	PRODIG (Prevention of new onset diabetes after transplantation by a short term treatment of) Tj ETQq1 1 0.784314 rgBT /Overlock 1 controlled study. <i>Trials</i> , 2019, 20, 375.	1.6	6
64	Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study. <i>American Journal of Transplantation</i> , 2019, 19, 3018-3034.	4.7	97
65	Temporal virus serological profiling of kidney graft recipients using VirScan. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 10899-10904.	7.1	16
66	Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies. <i>American Journal of Transplantation</i> , 2019, 19, 2865-2875.	4.7	67
67	Non-HLA agonistic anti-angiotensin II type 1 receptor antibodies induce a distinctive phenotype of antibody-mediated rejection in kidney transplant recipients. <i>Kidney International</i> , 2019, 96, 189-201.	5.2	117
68	Epitope load identifies kidney transplant recipients at risk of allosensitization following minimization of immunosuppression. <i>Kidney International</i> , 2019, 95, 1471-1485.	5.2	40
69	Dynamic predictions of long-term kidney graft failure: an information tool promoting patient-centred care. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1961-1969.	0.7	13
70	Impact of estimation versus direct measurement of predonation glomerular filtration rate on the eligibility of potential living kidney donors. <i>Kidney International</i> , 2019, 95, 896-904.	5.2	31
71	Response to treatment and long-term outcomes in kidney transplant recipients with acute T cell-mediated rejection. <i>American Journal of Transplantation</i> , 2019, 19, 1972-1988.	4.7	60
72	The Case Posttransplant upper limb inflammatory nodules. <i>Kidney International</i> , 2019, 95, 721-722.	5.2	0

#	ARTICLE	IF	CITATIONS
73	A Test Identifying Biomarkers of Immunosuppression-Related Adverse Events in Kidney Transplant Recipients. <i>Kidney International Reports</i> , 2019, 4, 1664-1665.	0.8	2
74	Conversion From Calcineurin Inhibitors to Belatacept in HLA-sensitized Kidney Transplant Recipients With Low-level Donor-specific Antibodies. <i>Transplantation</i> , 2019, 103, 2150-2156.	1.0	18
75	GFR Assessment of Living Kidney Donors Candidates. <i>Transplantation</i> , 2019, 103, 1086-1093.	1.0	13
76	Membranous Nephropathy Posttransplantation: An Update of the Pathophysiology and Management. <i>Transplantation</i> , 2019, 103, 1990-2002.	1.0	29
77	No clinical benefit of rapid versus gradual tapering of immunosuppression to treat sustained BK virus viremia after kidney transplantation: a single-center experience. <i>Transplant International</i> , 2019, 32, 481-492.	1.6	8
78	mTOR inhibitors may benefit kidney transplant recipients with mitochondrial diseases. <i>Kidney International</i> , 2019, 95, 455-466.	5.2	44
79	Baseline graft status is a critical predictor of kidney graft failure after diarrhoea. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1597-1604.	0.7	2
80	Lack of impact of pre-emptive deceased-donor kidney transplantation on graft outcomes: a propensity score-based study. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 886-891.	0.7	3
81	Reduction in late onset cytomegalovirus primary disease after discontinuation of antiviral prophylaxis in kidney transplant recipients treated with de novo everolimus. <i>Transplant Infectious Disease</i> , 2018, 20, e12846.	1.7	7
82	Propensity score-based comparison of the graft failure risk between kidney transplant recipients of standard and expanded criteria donor grafts: Toward increasing the pool of marginal donors. <i>American Journal of Transplantation</i> , 2018, 18, 1151-1157.	4.7	25
83	Post-Transplant Natural Antibodies Associate with Kidney Allograft Injury and Reduced Long-Term Survival. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1761-1770.	6.1	36
84	Conversion to Belatacept in Maintenance Kidney Transplant Patients. <i>Transplantation</i> , 2018, 102, 1545-1552.	1.0	43
85	Poor Patient and Graft Outcome After Induction Treatment by Antithymocyte Globulin in Recipients of a Kidney Graft After Nonrenal Organ Transplantation. <i>Transplantation Direct</i> , 2018, 4, e357.	1.6	12
86	T cell-mediated rejection is a major determinant of inflammation in scarred areas in kidney allografts. <i>American Journal of Transplantation</i> , 2018, 18, 377-390.	4.7	76
87	Safety of renal transplantation in patients with bipolar or psychotic disorders: a retrospective study. <i>Transplant International</i> , 2018, 31, 377-385.	1.6	12
88	Preemptive second kidney transplantation is associated with better graft survival compared with non-preemptive second transplantation: a multicenter French 2000-2014 cohort study. <i>Transplant International</i> , 2018, 31, 408-423.	1.6	22
89	Response to Renal allograft histology at 10 years after transplantation in the tacrolimus era: Evidence of pervasive chronic injury. <i>American Journal of Transplantation</i> , 2018, 18, 1292-1292.	4.7	0
90	Comparison of Postdonation Kidney Function Between Caucasian Donors and Low-risk APOL1 Genotype Living Kidney Donors of African Ancestry. <i>Transplantation</i> , 2018, 102, e462-e463.	1.0	5

#	ARTICLE	IF	CITATIONS
91	FP742 THE IMPACT OF AGE ON ACCEPTABLE MEASURED GFR FOR LIVING KIDNEY DONATION. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i296-i296.	0.7	0
92	Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection. <i>Kidney International</i> , 2018, 94, 773-787.	5.2	38
93	Analyses of the short- and long-term graft survival after kidney transplantation in Europe between 1986 and 2015. <i>Kidney International</i> , 2018, 94, 964-973.	5.2	198
94	Everolimus with Reduced Calcineurin Inhibitor Exposure in Renal Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 1979-1991.	6.1	193
95	FO051 THE IMPACT OF GFR EVALUATION TECHNIQUE ON LIVING KIDNEY DONATION ELIGIBILITY. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i39-i40.	0.7	0
96	The age-calibrated measured glomerular filtration rate improves living kidney donation selection process. <i>Kidney International</i> , 2018, 94, 616-624.	5.2	28
97	Use of computed tomography assessed kidney length to predict split renal GFR in living kidney donors. <i>European Radiology</i> , 2017, 27, 651-659.	4.5	13
98	Genome-Wide Association Study of Acute Renal Graft Rejection. <i>American Journal of Transplantation</i> , 2017, 17, 201-209.	4.7	50
99	Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1603-1613.	6.1	83
100	What is the significance of end-stage renal disease risk estimation in living kidney donors?. <i>Transplant International</i> , 2017, 30, 799-806.	1.6	6
101	Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1912-1923.	6.1	208
102	Paraganglioma of the bladder in a kidney transplant recipient: A case report. <i>Molecular and Clinical Oncology</i> , 2017, 6, 553-555.	1.0	11
103	Dual Kidney Transplantation: Is It Worth It?. <i>Transplantation</i> , 2017, 101, 488-497.	1.0	32
104	Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis. <i>Kidney International</i> , 2017, 92, 729-742.	5.2	43
105	Reversal of Arterial Stiffness and Maladaptive Arterial Remodeling After Kidney Transplantation. <i>Journal of the American Heart Association</i> , 2017, 6, .	3.7	24
106	Midterm Outcomes of 12 Renal Transplant Recipients Treated With Eculizumab to Prevent Atypical Hemolytic Syndrome Recurrence. <i>Transplantation</i> , 2017, 101, 2924-2930.	1.0	21
107	C5 nephritic factors drive the biological phenotype of C3 glomerulopathies. <i>Kidney International</i> , 2017, 92, 1232-1241.	5.2	93
108	The Association Between Fibroblast Growth Factor-23 and Renal Transplantation Outcome Is Modified by Follow-up Duration and Glomerular Filtration Rate Assessment Method. <i>Kidney International Reports</i> , 2017, 2, 881-892.	0.8	9

#	ARTICLE	IF	CITATIONS
109	Lung cancer in renal transplant recipients: A case-control study. Lung Cancer, 2017, 111, 96-100.	2.0	10
110	Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled<i>post hoc</i>analysis. Transplant International, 2017, 30, 1275-1283.	1.6	30
111	Reduction of Extended-Release Tacrolimus Dose in Low-Immunological-Risk Kidney Transplant Recipients Increases Risk of Rejection and Appearance of Donor-Specific Antibodies: A Randomized Study. American Journal of Transplantation, 2017, 17, 1370-1379.	4.7	85
112	Antiphospholipid syndrome and kidney disease. Kidney International, 2017, 91, 34-44.	5.2	44
113	Value of Donorâ€™Specific Antiâ€™HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss. Journal of the American Society of Nephrology: JASN, 2017, 28, 702-715.	6.1	111
114	Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic Screening. American Journal of Transplantation, 2017, 17, 1008-1019.	4.7	13
115	The role of complement inhibition in kidney transplantation. British Medical Bulletin, 2017, 124, 1-13.	6.9	9
116	Cancer After Kidney Transplantation. , 2017, , 525-542.		0
117	Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B. PLoS Neglected Tropical Diseases, 2016, 10, e0004304.	3.0	38
118	Estimated or Measured GFR in Living Kidney Donors Work-up?. American Journal of Transplantation, 2016, 16, 3024-3032.	4.7	30
119	Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype. American Journal of Transplantation, 2016, 16, 2670-2675.	4.7	51
120	Effect of an Early Switch to Belatacept Among Calcineurin Inhibitorâ€™Intolerant Graft Recipients of Kidneys From Extendedâ€™Criteria Donors. American Journal of Transplantation, 2016, 16, 2181-2186.	4.7	52
121	Association of mGFR of the Remaining Kidney Divided by Its Volume before Donation with Functional Gain in mGFR among Living Kidney Donors. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1369-1376.	4.5	16
122	Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial. American Journal of Kidney Diseases, 2016, 68, 84-93.	1.9	230
123	Generation of Catalytic Antibodies Is an Intrinsic Property of an Individualâ€™s Immune System: A Study on a Large Cohort of Renal Transplant Patients. Journal of Immunology, 2016, 196, 4075-4081.	0.8	3
124	The costimulatory receptor B7-1 is not induced in injured podocytes. Kidney International, 2016, 90, 1037-1044.	5.2	18
125	Renal safety of high-dose, sucrose-free intravenous immunoglobulin in kidney transplant recipients: an observational study. Transplant International, 2016, 29, 1205-1215.	1.6	7
126	Prognosis of Invasive Aspergillosis in Kidney Transplant Recipients: A Case-Control Study. Transplantation Direct, 2016, 2, e90.	1.6	12

#	ARTICLE	IF	CITATIONS
127	CD25 blockade in kidney transplant patients randomized to standard-dose or high-dose basiliximab with cyclosporine, or high-dose basiliximab in a calcineurin inhibitor-free regimen. <i>Transplant International</i> , 2016, 29, 184-195.	1.6	6
128	Pathogenesis of non-HLA antibodies in solid organ transplantation: Where do we stand?. <i>Human Immunology</i> , 2016, 77, 1055-1062.	2.4	26
129	Acquired Flucytosine Resistance during Combination Therapy with Caspofungin and Flucytosine for <i>Candida glabrata</i> Cystitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 662-665.	3.2	17
130	B7-1 Blockade Does Not Improve Post-Transplant Nephrotic Syndrome Caused by Recurrent FSGS. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 2520-2527.	6.1	75
131	Long-term CD4 lymphopenia is associated with accelerated decline of kidney allograft function. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 487-495.	0.7	23
132	IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 293-304.	6.1	244
133	Mortality Prediction after the First Year of Kidney Transplantation: An Observational Study on Two European Cohorts. <i>PLoS ONE</i> , 2016, 11, e0155278.	2.5	12
134	De Novo Donor-Specific Human Leukocyte Antigen Antibodies in Nonsensitized Kidney Transplant Recipients After T Cell-Mediated Rejection. <i>Transplantation</i> , 2015, 99, 965-972.	1.0	28
135	PREventing Delayed Graft Function by Driving Immunosuppressive Induction Treatment (PREDICT-DGF): study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 282.	1.6	8
136	Excellent long-term outcome of renal transplantation in cystinosis patients. <i>Orphanet Journal of Rare Diseases</i> , 2015, 10, 90.	2.7	27
137	A personalized follow-up of kidney transplant recipients using video conferencing based on a 1-year scoring system predictive of long term graft failure (TELEGRAFT study): protocol for a randomized controlled trial. <i>BMC Nephrology</i> , 2015, 16, 6.	1.8	21
138	Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study. <i>BMJ, The</i> , 2015, 351, h3557.	6.0	146
139	Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1721-1731.	6.1	243
140	Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. <i>Kidney International</i> , 2015, 87, 1061-1073.	5.2	342
141	Restricted specificity of peripheral alloreactive memory B cells in HLA-sensitized patients awaiting a kidney transplant. <i>Kidney International</i> , 2015, 87, 1230-1240.	5.2	39
142	AKT/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game. <i>Lupus</i> , 2015, 24, 227-230.	1.6	27
143	Urinary C-X-C Motif Chemokine 10 Independently Improves the Noninvasive Diagnosis of Antibody-Mediated Kidney Allograft Rejection. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 2840-2851.	6.1	112
144	Determinants and Outcomes of Accelerated Arteriosclerosis. <i>Circulation Research</i> , 2015, 117, 470-482.	4.5	41

#	ARTICLE	IF	CITATIONS
145	The emerging role of complement inhibitors in transplantation. <i>Kidney International</i> , 2015, 88, 967-973.	5.2	39
146	Each additional hour of cold ischemia time significantly increases the risk of graft failure and mortality following renal transplantation. <i>Kidney International</i> , 2015, 87, 343-349.	5.2	287
147	Prevalence and Predictors of Early Cardiovascular Events after Kidney Transplantation: Evaluation of Pre-Transplant Cardiovascular Work-Up. <i>PLoS ONE</i> , 2015, 10, e0131237.	2.5	38
148	TRANSFORM: a novel study design to evaluate the effect of everolimus on long-term outcomes after kidney transplantation. <i>Open Access Journal of Clinical Trials</i> , 2014, , 45.	1.5	19
149	Antibody-mediated vascular rejection of kidney allograft: characterization of different kidney allograft rejection phenotypes via histology, C4d deposition and donor-specific antibodies. <i>Clinical and Experimental Immunology</i> , 2014, 178, 59-60.	2.6	2
150	Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival. <i>Kidney International</i> , 2014, 85, 182-190.	5.2	35
151	A useful scoring system for the prediction and management of delayed graft function following kidney transplantation from cadaveric donors. <i>Kidney International</i> , 2014, 86, 1130-1139.	5.2	82
152	Outcome of Kidney Transplantations Performed With Preformed Donor-Specific Antibodies of Unknown Etiology. <i>American Journal of Transplantation</i> , 2014, 14, 193-201.	4.7	37
153	A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. <i>Science Translational Medicine</i> , 2014, 6, 256ra136.	12.4	172
154	Risk of Antibody-Mediated Rejection in Kidney Transplant Recipients With Anti-HLA-C Donor-Specific Antibodies. <i>American Journal of Transplantation</i> , 2014, 14, 1439-1445.	4.7	39
155	Factors influencing long-term outcome after kidney transplantation. <i>Transplant International</i> , 2014, 27, 19-27.	1.6	176
156	Antibody-mediated vascular rejection of kidney allografts: a population-based study. <i>Lancet</i> , The, 2013, 381, 313-319.	13.7	308
157	The First Transplant Kidney Biopsy Ever Performed. <i>American Journal of Transplantation</i> , 2013, 13, 1367-1368.	4.7	4
158	Complement-Binding Anti-HLA Antibodies and Kidney-Allograft Survival. <i>New England Journal of Medicine</i> , 2013, 369, 1215-1226.	27.0	746
159	Proteinuria in kidney transplantation: an ongoing story. <i>Nature Reviews Nephrology</i> , 2013, 9, 251-252.	9.6	9
160	Eculizumab in renal transplantation. <i>Transplantation Reviews</i> , 2013, 27, 90-92.	2.9	39
161	Eculizumab for Atypical Hemolytic Uremic Syndrome Recurrence in Renal Transplantation. <i>American Journal of Transplantation</i> , 2012, 12, 3337-3354.	4.7	223
162	Recurrence from primary and secondary glomerulopathy after renal transplant. <i>Transplant International</i> , 2012, 25, 812-824.	1.6	42

#	ARTICLE	IF	CITATIONS
163	New insights into postrenal transplant hemolytic uremic syndrome. <i>Nature Reviews Nephrology</i> , 2011, 7, 23-35.	9.6	169
164	Cytomegalovirus Incidence Between Everolimus Versus Mycophenolate in De Novo Renal Transplants: Pooled Analysis of Three Clinical Trials. <i>American Journal of Transplantation</i> , 2011, 11, 2453-2462.	4.7	135
165	Specificity of Histological Markers of Long-Term CNI Nephrotoxicity in Kidney Transplant Recipients Under Low-Dose Cyclosporine Therapy. <i>American Journal of Transplantation</i> , 2011, 11, 2635-2646.	4.7	101
166	Donor-Specific Antibodies Accelerate Arteriosclerosis after Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 975-983.	6.1	88
167	Combined Posttransplant Prophylactic IVIg/Anti-CD 20/Plasmapheresis in Kidney Recipients With Preformed Donor-Specific Antibodies: A Pilot Study. <i>Transplantation</i> , 2010, 89, 1403-1410.	1.0	133
168	Recurrence of nephrotic syndrome after transplantation in a mixed population of children and adults: course of glomerular lesions and value of the Columbia classification of histological variants of focal and segmental glomerulosclerosis (FSGS). <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1321-1328.	0.7	81
169	Effects of vitamin D supplementation on the calcium-phosphate balance in renal transplant patients. <i>Kidney International</i> , 2009, 75, 646-651.	5.2	99
170	Donor-Estimated GFR as an Appropriate Criterion for Allocation of ECD Kidneys into Single or Dual Kidney Transplantation. <i>American Journal of Transplantation</i> , 2009, 9, 2542-2551.	4.7	75
171	Outcome of Subclinical Antibody-Mediated Rejection in Kidney Transplant Recipients with Preformed Donor-Specific Antibodies. <i>American Journal of Transplantation</i> , 2009, 9, 2561-2570.	4.7	290
172	A Simple Clinico-Histopathological Composite Scoring System Is Highly Predictive of Graft Outcomes in Marginal Donors. <i>American Journal of Transplantation</i> , 2008, 8, 2325-2334.	4.7	116
173	mTOR inhibitors-induced proteinuria: mechanisms, significance, and management. <i>Transplantation Reviews</i> , 2008, 22, 125-130.	2.9	103
174	Kaposi sarcoma in transplantation. <i>Transplantation Reviews</i> , 2008, 22, 252-261.	2.9	123
175	Improving Outcomes for Solid-Organ Transplant Recipients At Risk from Cytomegalovirus Infection: Late-Onset Disease and Indirect Consequences. <i>Clinical Infectious Diseases</i> , 2008, 46, 732-740.	5.8	81
176	Determination of Lowest Possible Creatinine in Living-Donor Kidney Renal Transplant Recipients Based on Donor Kidney Function. <i>Transplantation</i> , 2008, 86, 558-563.	1.0	8
177	To Biopsy or Not to Biopsy? Should We Screen the Histology of Stable Renal Grafts?. <i>Transplantation</i> , 2007, 84, 671-676.	1.0	54
178	Efficacy and Safety of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Recipients: Pooled Data From Three 12-Month Multicenter, Open-Label, Prospective Studies. <i>Transplantation Proceedings</i> , 2007, 39, 1386-1391.	0.6	20
179	Posttransplant Prophylactic Intravenous Immunoglobulin in Kidney Transplant Patients at High Immunological Risk: A Pilot Study. <i>American Journal of Transplantation</i> , 2007, 7, 1185-1192.	4.7	55
180	Differences in the frequency and function of HHV8-specific CD8 T cells between asymptomatic HHV8 infection and Kaposi sarcoma. <i>Blood</i> , 2006, 108, 3871-3880.	1.4	66

#	ARTICLE	IF	CITATIONS
181	Sirolimus Conversion for Patients with Posttransplant Kaposi's Sarcoma. American Journal of Transplantation, 2006, 6, 2164-2168.	4.7	114
182	Kidney Transplant in Black Recipients: Are African Europeans Different from African Americans?. American Journal of Transplantation, 2005, 5, 2682-2687.	4.7	64
183	The cost-effectiveness of prophylaxis with valaciclovir in the management of cytomegalovirus after renal transplantation. European Journal of Health Economics, 2005, 6, 172-182.	2.8	8
184	Pharmacogenetics in Solid Organ Transplantation: Present Knowledge and Future Perspectives. Transplantation, 2004, 78, 311-315.	1.0	43
185	Prognostic Value of Quantitative Kaposi Sarcoma-associated Herpesvirus Load in Posttransplantation Kaposi Sarcoma. Journal of Infectious Diseases, 2002, 186, 110-113.	4.0	93
186	Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal Transplantation. New England Journal of Medicine, 1999, 340, 1462-1470.	27.0	681
187	HUMAN HERPES VIRUS-8 AND OTHER RISK FACTORS FOR KAPOSI'S SARCOMA IN KIDNEY TRANSPLANT RECIPIENTS. Transplantation, 1999, 67, 1236-1242.	1.0	107
188	HARMFUL LONG-TERM IMPACT OF HEPATITIS C VIRUS INFECTION IN KIDNEY TRANSPLANT RECIPIENTS. Transplantation, 1998, 65, 667-670.	1.0	233
189	Acyclovir in preventing cytomegalovirus infection in kidney transplant recipients: A case-controlled study. Journal of Medical Virology, 1993, 41, 118-122.	5.0	7
190	Acyclovir in preventing cytomegalovirus infection in kidney transplant recipients: a case-controlled study. Transplantation Proceedings, 1993, 25, 1431-3.	0.6	10
191	Sequential measurements of urinary albumin in recipients of renal allografts. Clinical Chemistry, 1991, 37, 472-473.	3.2	3
192	First dose OKT3-induced release of endothelin in renal transplant recipients. Nephrology Dialysis Transplantation, 0, , .	0.7	0